Anna Magdalena Sigmund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna Magdalena Sigmund has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Franziska Vielmuth
Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilians-Universität München , Munich
6 shared publications - Jens Waschke
Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, LMU Munich, Munich, Germany
6 shared publications Amir S. Yazdi
Department of Dermatology, Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) Aachen University, Aachen, Germany
3 shared publicationsDaniela Kugelmann
Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, LMU Munich, Munich, Germany
3 shared publicationsDesalegn T. Egu
Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, LMU Munich, Munich, Germany
3 shared publications- Enno Schmidt
Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
3 shared publications
Latest Publications
- Open Access
- 25 April 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (12) , 2682-2694.e10
Desmosomal Hyper-Adhesion Affects Direct Inhibition of Desmoglein Interactions in Pemphigus
- 25 April 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (12) , 2682-2694.e10
Open AccessDesmosomal Hyper-Adhesion Affects Direct Inhibition of Desmoglein Interactions in Pemphigus
- Open Access
- 19 April 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (11) , 2440-2452
EGFR Inhibition by Erlotinib Rescues Desmosome Ultrastructure and Keratin Anchorage and Protects against Pemphigus Vulgaris IgG–Induced Acantholysis in Human Epidermis
- 19 April 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (11) , 2440-2452
Open AccessEGFR Inhibition by Erlotinib Rescues Desmosome Ultrastructure and Keratin Anchorage and Protects against Pemphigus Vulgaris IgG–Induced Acantholysis in Human Epidermis
- Open Access
- 11 July 2023
- Published by Wiley in Acta Physiologica
- Vol. 238 (4) , e14006
cAMP: A master regulator of cadherin‐mediated binding in endothelium, epithelium and myocardium
Regulation of cadherin‐mediated cell adhesion is crucial not only for maintaining tissue integrity and barrier function in the endothelium and epithelium but also for electromechanical coupling within the myocardium. Therefore, loss of cadherin‐mediated adhesion causes various disorders, including vascular inflammation and desmosome‐related diseases such as the autoimmune blistering skin dermatosis pemphigus and arrhythmogenic cardiomyopathy. Mechanisms regulating cadherin‐mediated binding contribute to the pathogenesis of diseases and may also be used as therapeutic targets. Over the last 30 years, cyclic adenosine 3′,5′‐monophosphate (cAMP) has emerged as one of the master regulators of cell adhesion in endothelium and, more recently, also in epithelial cells as well as in cardiomyocytes. A broad spectrum of experimental models from vascular physiology and cell biology applied by different generations of researchers provided evidence that not only cadherins of endothelial adherens junctions (AJ) but also desmosomal contacts in keratinocytes and the cardiomyocyte intercalated discs are central targets in this scenario. The molecular mechanisms involve protein kinase A‐ and exchange protein directly activated by cAMP‐mediated regulation of Rho family GTPases and S665 phosphorylation of the AJ and desmosome adaptor protein plakoglobin. In line with this, phosphodiesterase 4 inhibitors such as apremilast have been proposed as a therapeutic strategy to stabilize cadherin‐mediated adhesion in pemphigus and may also be effective to treat other disorders where cadherin‐mediated binding is compromised.
- 11 July 2023
- Published by Wiley in Acta Physiologica
- Vol. 238 (4) , e14006
Open AccesscAMP: A master regulator of cadherin‐mediated binding in endothelium, epithelium and myocardium
Regulation of cadherin‐mediated cell adhesion is crucial not only for maintaining tissue integrity and barrier function in the endothelium and epithelium but also for electromechanical coupling within the myocardium. Therefore, loss of cadherin‐mediated adhesion causes various disorders, including vascular inflammation and desmosome‐related diseases such as the autoimmune blistering skin dermatosis pemphigus and arrhythmogenic cardiomyopathy. Mechanisms regulating cadherin‐mediated binding contribute to the pathogenesis of diseases and may also be used as therapeutic targets. Over the last 30 years, cyclic adenosine 3′,5′‐monophosphate (cAMP) has emerged as one of the master regulators of cell adhesion in endothelium and, more recently, also in epithelial cells as well as in cardiomyocytes. A broad spectrum of experimental models from vascular physiology and cell biology applied by different generations of researchers provided evidence that not only cadherins of endothelial adherens junctions (AJ) but also desmosomal contacts in keratinocytes and the cardiomyocyte intercalated discs are central targets in this scenario. The molecular mechanisms involve protein kinase A‐ and exchange protein directly activated by cAMP‐mediated regulation of Rho family GTPases and S665 phosphorylation of the AJ and desmosome adaptor protein plakoglobin. In line with this, phosphodiesterase 4 inhibitors such as apremilast have been proposed as a therapeutic strategy to stabilize cadherin‐mediated adhesion in pemphigus and may also be effective to treat other disorders where cadherin‐mediated binding is compromised.
- Open Access
- 7 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Author Correction: Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus
- 7 February 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Open AccessAuthor Correction: Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus
- Open Access
- 9 January 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus
Pemphigus vulgaris is a life-threatening blistering skin disease caused by autoantibodies destabilizing desmosomal adhesion. Current therapies focus on suppression of autoantibody formation and thus treatments directly stabilizing keratinocyte adhesion would fulfill an unmet medical need. We here demonstrate that apremilast, a phosphodiesterase 4 inhibitor used in psoriasis, prevents skin blistering in pemphigus vulgaris. Apremilast abrogates pemphigus autoantibody-induced loss of keratinocyte cohesion in ex-vivo human epidermis, cultured keratinocytes in vitro and in vivo in mice. In parallel, apremilast inhibits keratin retraction as well as desmosome splitting, induces phosphorylation of plakoglobin at serine 665 and desmoplakin assembly into desmosomal plaques. We established a plakoglobin phospho-deficient mouse model that reveals fragile epidermis with altered organization of keratin filaments and desmosomal cadherins. In keratinocytes derived from these mice, intercellular adhesion is impaired and not rescued by apremilast. These data identify an unreported mechanism of desmosome regulation and propose that apremilast stabilizes keratinocyte adhesion and is protective in pemphigus.
- 9 January 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Open AccessApremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus
Pemphigus vulgaris is a life-threatening blistering skin disease caused by autoantibodies destabilizing desmosomal adhesion. Current therapies focus on suppression of autoantibody formation and thus treatments directly stabilizing keratinocyte adhesion would fulfill an unmet medical need. We here demonstrate that apremilast, a phosphodiesterase 4 inhibitor used in psoriasis, prevents skin blistering in pemphigus vulgaris. Apremilast abrogates pemphigus autoantibody-induced loss of keratinocyte cohesion in ex-vivo human epidermis, cultured keratinocytes in vitro and in vivo in mice. In parallel, apremilast inhibits keratin retraction as well as desmosome splitting, induces phosphorylation of plakoglobin at serine 665 and desmoplakin assembly into desmosomal plaques. We established a plakoglobin phospho-deficient mouse model that reveals fragile epidermis with altered organization of keratin filaments and desmosomal cadherins. In keratinocytes derived from these mice, intercellular adhesion is impaired and not rescued by apremilast. These data identify an unreported mechanism of desmosome regulation and propose that apremilast stabilizes keratinocyte adhesion and is protective in pemphigus.
- Open Access
Apremilast prevents blistering in human epidermis by stabilization of keratinocyte adhesion in pemphigus
Pemphigus vulgaris (PV) is a life-threatening blistering skin disease caused by autoantibodies (PV-IgG) destabilizing desmosomal adhesion. Current therapies focus on suppression of autoantibody formation and thus treatments directly stabilizing keratinocyte adhesion would fulfill an unmet medical need. We here demonstrate that apremilast, a phosphodiesterase 4 inhibitor used e.g. in psoriasis, prevents blistering in PV. Apremilast abrogated PV-IgG-induced loss of keratinocyte cohesion in ex-vivo epidermis and in vitro . This was paralleled by inhibition of keratin retraction and desmosome splitting but affected neither desmoglein (Dsg) depletion nor Dsg3 binding properties. Apremilast induced phosphorylation of plakoglobin at serine 665 – a mechanisms which is known to stabilize cardiomyocyte cohesion. Interestingly, keratinocytes phospho-deficient at this side showed altered organization of Dsg1, Dsg3 and keratin filaments and impaired adhesion, which was not rescued by apremilast. These data identified a new mechanism of desmosome regulation and propose that apremilast is protective in pemphigus by stabilizing keratinocyte cohesion.
Open AccessApremilast prevents blistering in human epidermis by stabilization of keratinocyte adhesion in pemphigus
Pemphigus vulgaris (PV) is a life-threatening blistering skin disease caused by autoantibodies (PV-IgG) destabilizing desmosomal adhesion. Current therapies focus on suppression of autoantibody formation and thus treatments directly stabilizing keratinocyte adhesion would fulfill an unmet medical need. We here demonstrate that apremilast, a phosphodiesterase 4 inhibitor used e.g. in psoriasis, prevents blistering in PV. Apremilast abrogated PV-IgG-induced loss of keratinocyte cohesion in ex-vivo epidermis and in vitro . This was paralleled by inhibition of keratin retraction and desmosome splitting but affected neither desmoglein (Dsg) depletion nor Dsg3 binding properties. Apremilast induced phosphorylation of plakoglobin at serine 665 – a mechanisms which is known to stabilize cardiomyocyte cohesion. Interestingly, keratinocytes phospho-deficient at this side showed altered organization of Dsg1, Dsg3 and keratin filaments and impaired adhesion, which was not rescued by apremilast. These data identified a new mechanism of desmosome regulation and propose that apremilast is protective in pemphigus by stabilizing keratinocyte cohesion.